NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease
- Univ. of Texas, M.D. Anderson Cancer Center, Houston (USA)
Patients with early-staged Hodgkin's disease have had a higher relapse rate following radiotherapy alone if they have B symptoms, large mediastinal masses, hilar involvement, or stage III disease. From June 1988 to December 1989, 27 previously untreated patients with early-staged Hodgkin's disease with adverse features for disease-free survival received combined-modality therapy. Seventeen patients had stage I or II disease, 10 had stage III, 5 had B symptoms, 13 had large mediastinal masses, and 6 had peripheral masses measuring 10 cm or more in diameter. All patients initially received three cycles of a novel chemotherapeutic regimen combining Novantrone (mitoxantrone, American Cyanamid Company), vincristine, vinblastine, and prednisone (NOVP). Twenty-four patients with clinically staged I or II disease with adverse features or stage III disease did not undergo laparotomy; three patients had favorable stage I or II disease and at laparotomy had stage III disease. Radiotherapy-treatment fields depended on the extent of nodal involvement. Twenty-six patients completed all therapy as planned to complete remission (CR) and one of these has had progression; she is in second CR following additional radiotherapy. With a median follow-up of 12 months, all patients are alive. Tolerance to treatment was excellent with only grade 1 or 2 nausea, alopecia and myalgias, and brief myelosuppression. NOVP is an effective adjuvant chemotherapy regimen for inducing responses, with minimal toxicity, prior to definitive radiotherapy for patients with early-staged Hodgkin's disease.
- OSTI ID:
- 6210398
- Journal Information:
- Seminars in Oncology; (USA), Vol. 17:6 Suppl 10; ISSN 0093-7754
- Country of Publication:
- United States
- Language:
- English
Similar Records
Non-Hodgkin's lymphoma, poorly differentiated lymphocytic and mixed cell types. Results of sequential staging procedures, response to therapy, and survival of 100 patients
Treatment of stage i and ii mediastinal Hodgkin disease: a comparison of involved fields, extended fields, and involved fields followed by MOPP in patients stage by laparotomy
Related Subjects
HODGKINS DISEASE
COMBINED THERAPY
ANTINEOPLASTIC DRUGS
LYMPHOCYTES
MAN
PATIENTS
SURVIVAL CURVES
ANIMAL CELLS
ANIMALS
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BODY FLUIDS
CONNECTIVE TISSUE CELLS
DISEASES
DRUGS
IMMUNE SYSTEM DISEASES
LEUKOCYTES
LYMPHOMAS
MAMMALS
MATERIALS
NEOPLASMS
PRIMATES
SOMATIC CELLS
THERAPY
VERTEBRATES
550603* - Medicine- External Radiation in Therapy- (1980-)
550600 - Medicine